ĀÜĄņĀŅĀ×

George Petrocheilos is a Co-Founder & Managing Partner of Catalio Capital Management, LP. He is primarily responsible for managing the firm and for making investments in breakthrough biomedical technology companies founded by world renowned scientist-entrepreneurs. He also serves on the Nexus Investment Committee and the firmwide Management Committee.

In addition to Octant, George currently serves on the Boards of Haystack Oncology, Spiral Therapeutics, MindX, DNA Script, Sisu Global Health, Inc., WindMIL Therapeutics, and LifeSprout. He also serves as President of the HealthCor Catalio Special Purpose Acquisition Corp. (NASDAQ: HCAQ) and on the Board of Directors of the family-owned PETKA S.A., a construction & development company headquartered in Athens, Greece.

Prior to founding Catalio, he was a General Partner at Camden Partners Holdings, LLC, a private equity firm, where he focused on making biomedical technology investments.

George serves on the Board of Trustees of the Kennedy Krieger Institute, the Baltimore School for the Arts and the Johns Hopkins Center for Financial Economics. He also serves on the Investment Advisory Committee of the Halcyon Incubator in Washington D.C. and the MIT Enterprise Forum. Georgeā€™s honors include Baltimore Business Journalā€™s 2019 ā€˜Tech 10ā€™ leaders in Maryland, BBJā€™s 2013 ā€œ40 Under 40 Business Leadersā€ and The Hillā€™s 2013 ā€œWashington D.C. Rising Starsā€, among others.

George earned his B.A. degree in Financial Economics from the Johns Hopkins University.